William Blair Has Positive Outlook for IQVIA Q4 Earnings

IQVIA Holdings Inc. (NYSE:IQV) – Stock analysts at William Blair boosted their Q4 2024 EPS estimates for shares of IQVIA in a research report issued on Wednesday, December 11th. William Blair analyst M. Smock now expects that the medical research company will post earnings of $2.83 per share for the quarter, up from their previous estimate of $2.82. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for IQVIA’s current full-year earnings is $10.18 per share. William Blair also issued estimates for IQVIA’s Q1 2025 earnings at $2.37 EPS.

A number of other analysts also recently weighed in on IQV. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Redburn Atlantic began coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Robert W. Baird reduced their price target on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. The Goldman Sachs Group dropped their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Barclays decreased their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $256.19.

IQVIA Trading Down 1.0 %

NYSE:IQV opened at $197.09 on Monday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The firm has a market capitalization of $35.77 billion, a price-to-earnings ratio of 25.86, a PEG ratio of 2.05 and a beta of 1.49. The business’s 50-day moving average price is $211.68 and its two-hundred day moving average price is $224.03.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oddo BHF Asset Management Sas bought a new stake in shares of IQVIA in the 3rd quarter valued at about $2,771,000. Franklin Resources Inc. raised its stake in IQVIA by 1.2% in the third quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company’s stock valued at $117,031,000 after buying an additional 6,011 shares during the period. Tidal Investments LLC lifted its position in shares of IQVIA by 9.3% in the third quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company’s stock valued at $1,417,000 after buying an additional 509 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of IQVIA during the 3rd quarter worth approximately $2,310,000. Finally, Arvest Bank Trust Division acquired a new position in shares of IQVIA during the 3rd quarter worth approximately $21,079,000. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.